reMYND   Report issue

For profit Phase 2
Founded: Leuven Belgium (2012)

Organization Overview

First Clinical Trial
2020
NCT04672135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

reMYND

Active Ingredients

Drugs in Phase 2 Trials (1)

rem0046127 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1